| Product identity | The material should be clearly identified as hyaluronic acid or sodium hyaluronate with a defined oligosaccharide or molecular-weight range. | Specification sheet, product code, structural description, and batch-specific certificate of analysis. | The identity, form, grade, and molecular-weight range are consistent across all documents. | “Low molecular weight” is stated without a numerical range or analytical method. |
| Molecular-weight distribution | A numerical target should be agreed before purchase because molecular weight affects performance, handling, and biological evaluation. | Test report using a stated method such as size-exclusion chromatography with appropriate calibration. | The measured result falls within the approved specification and includes method details. | Only viscosity is reported as a substitute for molecular-weight testing. |
| Source and raw materials | The supplier should disclose whether the hyaluronic acid is produced by controlled microbial fermentation and identify the material inputs used in production. | Manufacturing-flow summary, raw-material statement, allergen statement, and animal-origin declaration. | The source and processing route are documented and suitable for the intended application. | The supplier cannot describe the production route or raw-material controls. |
| Microbiological quality | Microbial limits must match the intended use, dosage form, and applicable regulatory or pharmacopeial requirements. | Batch-specific total aerobic microbial count, total yeast and mold count, and specified-organism test results. | Results comply with the approved specification and the method is identified. | Generic statements such as “microbiologically safe” without numerical results. |
| Endotoxin control | Endotoxin limits should be based on the final route of administration and product-specific risk assessment; injectable applications require particularly stringent control. | Validated bacterial endotoxin test report, limit specification, and sample-preparation information. | The result is below the approved limit and the test is suitable for the product matrix. | Endotoxin is not tested, or the supplier provides only a non-numerical declaration. |
| Residual proteins and nucleic acids | Process-related impurities should be controlled with product-specific limits, especially when the material is intended for sensitive applications. | Protein, nucleic-acid, and process-residue test results with analytical methods. | Each impurity has a defined limit, test method, and batch result. | The supplier reports only purity while omitting process-related impurities. |
| Heavy metals and elemental impurities | Elemental impurities should be assessed according to the intended application and relevant regulatory expectations. | Risk assessment and test results for relevant elements, typically measured by ICP-MS or an equivalent validated technique. | Results meet the agreed limits and are supported by a recognized analytical method. | A single “heavy metals pass” statement lacks analyte details and detection limits. |
| Residual solvents and processing chemicals | Potential solvents, cross-linking agents, cleaning residues, and other process chemicals should be identified and controlled. | Residual-solvent declaration, process-risk assessment, and chromatographic test results where applicable. | All relevant residues are either absent, below specification, or scientifically justified. | The supplier refuses to disclose process chemicals under a broad confidentiality claim. |
| Purity and composition | Purity should be defined by a stated analytical method rather than by an unsupported percentage claim. | Assay method, water content, ash or inorganic residue, and batch-specific results. | The specification distinguishes active content from moisture, salts, and other excipients. | “Purity above 99%” is provided without a definition or test method. |
| Stability and shelf life | Shelf life should be supported by stability data under the proposed packaging and storage conditions. | Stability protocol, time-point results, recommended temperature, humidity limits, and retest or expiry date. | Identity, molecular weight, moisture, appearance, and microbiological quality remain within specification. | Shelf life is assigned without supporting stability information. |
| Packaging and storage | Packaging should protect the powder or solution from moisture, contamination, light, and unsuitable temperature exposure. | Packaging specification, container-closure information, storage instructions, and transport conditions. | Packaging is intact, tamper-evident where required, and labeled with batch and expiry information. | Unsealed containers, unclear storage conditions, or repeated moisture exposure during transit. |
| Quality management system | The supplier should operate a documented quality system appropriate to the intended product category and risk level. | Quality manual or questionnaire, audit report, certification scope, deviation procedure, and change-control procedure. | The certification or audit scope covers the actual manufacturing and testing site. | A certificate is presented without scope, site address, validity, or audit details. |
| Batch traceability | Every shipment should be traceable from incoming raw materials through processing, testing, release, and distribution. | Batch-number format, manufacturing date, release record, retained-sample policy, and traceability procedure. | The supplier can link the delivered batch to production and test records. | Batch numbers are missing, duplicated, or inconsistent across labels and certificates. |
| Certificate of analysis | Each batch should be released against an approved specification using actual test results rather than copied or estimated values. | Signed batch certificate showing specification limits, actual results, methods, dates, and authorized approval. | The certificate is batch-specific, complete, internally consistent, and verifiable. | Every batch has identical numerical results or the document contains unexplained alterations. |
| Independent verification | A qualified independent laboratory should confirm critical attributes before commercial approval or when supplier risk is high. | Independent test report for identity, molecular-weight distribution, microbiology, endotoxin, and key impurities as applicable. | Independent results are consistent with the supplier’s certificate within predefined laboratory tolerances. | The supplier rejects reasonable verification requests or supplies only promotional data. |
| Regulatory and intended-use fit | The grade, documentation, labeling, and safety data must match the intended use, such as cosmetic, oral, topical, or parenteral application. | Regulatory status statement, safety data sheet where applicable, intended-use limitations, and market-specific documentation. | The supplier clearly distinguishes grades and does not claim suitability beyond the available evidence. | A cosmetic-grade material is promoted as suitable for sterile or injectable use without supporting controls. |
| Change notification and complaint handling | The supplier should notify customers before significant changes to raw materials, process, site, specification, packaging, or test methods. | Change-control agreement, complaint procedure, recall procedure, and response-time commitment. | Responsibilities, notification periods, investigation steps, and corrective actions are documented. | The supplier can change the process or manufacturing site without prior notice. |
